Molecular Partners AG (MOLN) stock
MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.09+0.00 (0.00%)
Close on Nov 11, 2026Market cap $124.76MP/E –Yield –
Molecular Partners EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -1.65 CHF. The highest annual figure on record is 3.54 CHF in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1.65 CHF | – |
| FY2024 | Dec 31, 2024 | -1.59 CHF | – |
| FY2023 | Dec 31, 2023 | -1.89 CHF | -153.4% |
| FY2022 | Dec 31, 2022 | 3.54 CHF | – |
| FY2021 | Dec 31, 2021 | -2.06 CHF | – |
| FY2020 | Dec 31, 2020 | -2.51 CHF | – |
| FY2019 | Dec 31, 2019 | -1.69 CHF | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -0.35 CHF | – |
| Q2 FY2025 | Jun 30, 2025 | -0.56 CHF | – |
| Q2 FY2024 | Jun 30, 2024 | -0.46 CHF | – |
| Q2 FY2023 | Jun 30, 2023 | -0.49 CHF | – |
| Q2 FY2022 | Jun 30, 2022 | -0.14 CHF | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?